Results 1 to 10 of about 148,764 (203)

The Impact of Upfront DihydroPyrimidine Dehydrogenase (DPD) Testing on the Therapeutic Management of Patients Scheduled for 5-FU. [PDF]

Cancer Med
ABSTRACT Purpose 5‐fluorouracil (5‐FU) is catabolized by dihydropyrimidine dehydrogenase (DPD). DPD deficiency can trigger life‐threatening toxicities, and pretesting DPD is increasingly recommended. Here, we investigated the impact of upfront DPD testing on treatment strategy, that is, whether DPD status influences physicians' choice to use 5‐FU or ...
Kallee G, Salas S, Milano G, Duffaud F, Dahan L, Ciccolini J.   +5 more
europepmc   +2 more sources

Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics [PDF]

Exploration of Targeted Anti-tumor Therapy
Fluoropyrimidines, crucial in cancer treatment, often cause toxicity concerns even at standard doses. Toxic accumulation of fluoropyrimidine metabolites, culminating in adverse effects, can stem from impaired dihydropyrimidine dehydrogenase (DPYD ...
Annalaura Montella, Sueva Cantalupo, Giuseppe D’Alterio, Vincenzo Damiano, Achille Iolascon, Mario Capasso   +5 more
doaj   +2 more sources

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase [PDF]

Clinical and Translational Science, 2022
Five‐fluorouracil (5‐FU) is a chemotherapeutic agent that is mainly metabolized by the rate‐limiting enzyme dihydropyrimidine dehydrogenase (DPD). The DPD enzyme activity deficiency involves a wide range of severities.
Jihyun Kang, Andrew HyoungJin Kim, Inseung Jeon, Jaeseong Oh, In‐Jin Jang, SeungHwan Lee, Joo‐Youn Cho   +6 more
doaj   +2 more sources

Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine [PDF]

Cancer Reports
Background This study evaluated awareness, prevalence, and utilization of dihydropyrimidine dehydrogenase (DPD) testing and pharmacogenomics among oncologists, residents, and clinical pharmacists working in Palestinian hospitals.
Mohammad Dweib, Hussein Hallak, Hani Hour, Asmahan Alzeer, Raya Fatafta, Leen Albaw   +5 more
doaj   +2 more sources

Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia [PDF]

Cancer Reports, 2023
Background Fluoropyrimidines (FP) are among the most common class of prescribed anti‐neoplastic drugs. This class has severe to moderate toxicity in around 10%–40% of those who take 5‐fluorouracil (5‐FU) or capecitabine for the treatment of cancer.
Hatouf H. Sukkarieh, Turki AlSagoor, Mohammed Alnuhait, Rami Bustami, Scott Bryson, Fatima Mohammed Kebir Adem, Hana Abdalla, Gulsan Karbani   +7 more
doaj   +2 more sources

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door. [PDF]

Ecancermedicalscience, 2022
Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is gaining importance as predictors of fluoropyrimidine-associated toxicity. The recommendation of dose adjustment for chemotherapy guided by the presence of polymorphisms of the DPYD gene can potentially improve treatment safety for a large number of patients, saving lives ...
Donadio MDS, Carraro DM, Torrezan GT, de Mello CAL.   +3 more
europepmc   +4 more sources

Uncovering the roles of dihydropyrimidine dehydrogenase in fatty-acid induced steatosis using human cellular models [PDF]

Scientific Reports, 2022
Pyrimidine catabolism is implicated in hepatic steatosis. Dihydropyrimidine dehydrogenase (DPYD) is an enzyme responsible for uracil and thymine catabolism, and DPYD human genetic variability affects clinically observed toxicity following 5-Fluorouracil ...
Kelly E. Sullivan, Sheetal Kumar, Xin Liu, Ye Zhang, Emily de Koning, Yanfei Li, Jing Yuan, Fan Fan   +7 more
doaj   +2 more sources

Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report

Frontiers in Oncology, 2019
Variations in the activity, up to absolute deficiency, of the enzyme dihydropyrimidine dehydrogenase (DPD), result in the occurrence of adverse reactions to chemotherapy, and have been included among the pharmacogenetic factors underlying inter ...
Francesco Silvestris, Domenica Lovero, Raffaele Palmirotta   +2 more
exaly   +3 more sources

A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report [PDF]

BMC Medical Genomics
Background Dihydropyrimidine dehydrogenase (DPD), is the initial and rate-limiting enzyme in the catabolic pathway of pyrimidines. Deleterious variants in the DPYD gene cause DPD deficiency, a rare autosomal recessive disorder.
Anna Malekkou, Marios Tomazou, Gavriella Mavrikiou, Maria Dionysiou, Theodoros Georgiou, Ioannis Papaevripidou, Angelos Alexandrou, Carolina Sismani, Anthi Drousiotou, Olga Grafakou, Petros P. Petrou   +10 more
doaj   +2 more sources

Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study [PDF]

Cancer Medicine
Introduction In April 2019, French authorities mandated dihydropyrimidine dehydrogenase (DPD) screening, specifically testing uracilemia, to mitigate the risk of toxicity associated with fluoropyrimidine‐based chemotherapy. However, this subject is still
Côme De Metz, Benjamin Hennart, Estelle Aymes, Pierre‐Yves Cren, Niels Martignène, Nicolas Penel, Maël Barthoulot, Aurélien Carnot   +7 more
doaj   +2 more sources